| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: OMER |
| Security Type |
Common Stock |
| Lead Underwriter |
Deutsche Bank Securities Corp |
| Days In Registration |
637 |
| Date Filed |
9-Jan-2008 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2008) |
| Industry |
Manufacturing |
| Business Description |
Omeros Corporation, located and incorporated in Seattle, Washington, is a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
21.29M |
| Contact |
- |
| Number of Employees |
- |
|
| Original Filing Information |
| US |
| Shares Filed |
- |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
- |
| · As a Percent |
- |
| Overallotment Shares Filed |
1023.0K |
| File Amount |
- |
| File Price Range |
- - - |
| File Mid Price |
- |
Current Filing Information
(Amended 2-Oct-2009) |
|
US |
|
Shares Filed |
6.82M |
| Secondary Shares Filed |
- |
| · As a Percent |
- |
| Primary Shares Filed |
6.82M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
- |
| File Amount |
$75.02M |
| · % Change from Original |
|
| File Price Range |
$12.00 - $10.00 |
| File Mid Price |
$11.00 |
|
